Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), among the world’s leading suppliers of reagents which enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the debut of its custom contract agency to rapidly develop antigen panels for influenza A and B viruses. This new service provides scientists access to high quality proteins from appearing seasonal and pandemic influenza strains, to encourage continuing research and development of diagnostics and vaccines.
Understanding existing influenza strains and having access to the corresponding antigens is vital to help distinguish infection from that of other respiratory diseases, and to enable accurate diagnosis and treatment. The Native Antigen Company is pleased to extend its custom contract service offering to now include the rapid development of influenza A and B antigens. We have worked hard to ensure our development capabilities can keep pace with emerging influenza strains and are proud to be able to produce a broad spectrum of high-quality proteins within a matter of weeks.”
Dr Andy Lane, Commercial Director, The Native Antigen Company
The Native Antigen Company offers custom contract solutions to produce panels of the flu antigens from a vast assortment of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which can introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins. ) The business has already used this recombinant protein expression system to successfully create a selection of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal influenza epidemics every year. Its custom contract service can help researchers working together with particular strains of influenza gain rapid access to highly purified proteins to conduct thorough assessments of immune responses with diagnostics, such as hepatitis responses to certain breeds.
The Native Antigen Company
